Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization

J Microbiol Immunol Infect. 2015 Apr;48(2):183-9. doi: 10.1016/j.jmii.2013.08.003. Epub 2013 Sep 21.

Abstract

Background: Patients with toxigenic Clostridium difficile colonization (tCDC) are at risk of developing C. difficile-associated diarrhea (CDAD). However, the risk factors of hospitalized patients with tCDC developing CDAD are not clear.

Methods: We conducted an 18-month prospective study at a medical ward in a district hospital in southern Taiwan. Within 48 hours of admission, weekly stool samples from asymptomatic hospitalized patients were obtained to detect fecal CDC. A polymerase chain reaction for tcdB was performed to determine toxigenic isolates. CDAD was diagnosed if the patient had diarrhea and toxigenic C. difficile present in a stool sample.

Results: A total 483 patients with stool samples were eligible for the study. Eighty-six (17.8%) patients had tCDC after screening, of whom 14 (16.3%) developed CDAD during follow-up. Among those with tCDC, patients with subsequent CDAD were more likely to have diabetes mellitus (p = 0.01) and to have received piperacillin-tazobactam (p = 0.04), or proton-pump inhibitors (PPIs; p = 0.04) than those without developing CDAD. The variables were statistically significant as determined by multivariate analysis. However, the 60-day crude mortality rates among tCDC patients with and without subsequent development of CDAD were similar.

Conclusion: Diabetes mellitus and recent receipt of piperacillin-tazobactam or PPIs are independent risk factors for the development of CDAD among hospitalized patients with tCDC.

Keywords: Clostridium difficile colonization; Clostridium difficile infection; Piperacillin-tazobactam; Proton-pump inhibitors; Risk factors.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics*
  • Bacterial Toxins / genetics*
  • Clostridioides difficile / isolation & purification*
  • Clostridium Infections / epidemiology*
  • Clostridium Infections / microbiology
  • Diabetes Complications
  • Diarrhea / epidemiology*
  • Diarrhea / microbiology
  • Feces / microbiology*
  • Female
  • Hospitalization
  • Hospitals, District
  • Humans
  • Male
  • Middle Aged
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / therapeutic use
  • Piperacillin / therapeutic use
  • Piperacillin, Tazobactam Drug Combination
  • Polymerase Chain Reaction
  • Prospective Studies
  • Proton Pump Inhibitors / therapeutic use
  • Risk Factors
  • Taiwan / epidemiology

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Bacterial Toxins
  • Proton Pump Inhibitors
  • toxB protein, Clostridium difficile
  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid
  • Piperacillin